1-methyltryptophan has been researched along with Malignant Melanoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Almquist, DR; Block, MS; Bryce, AH; DeLeon, TT; Dronca, RS; Joseph, RW; Kipp, BR; Kosiorek, HE; Kottschade, LA; Langlais, BT; Mangold, A; Markovic, SN; McWilliams, RR; Rumilla, KM; Seetharam, M; Sekulic, A; Voss, JS; Winters, JL | 1 |
| Campa, A; Consolaro, MEL; da Costa Souza, P; Faião-Flores, F; Felipe-Silva, A; Maria-Engler, SS; Migliorini, S; Oliveira, EA; Sandri, S; Tiago, M; Vazquez, VL; Watanabe, LRM | 1 |
| Feng, X; He, X; Li, Y; Qi, D; Shen, X; Xia, X; Zeng, Z; Zhou, Z; Zhu, C | 1 |
| Brincks, EL; Drabick, J; Grossmann, KF; Kennedy, EP; Kolhe, R; Link, CJ; McWilliams, RR; Milhem, M; Munn, D; Pacholczyk, R; Rixe, O; Rossi, GR; Sadek, R; Shaheen, MF; Shen, SS; Smith, CM; Tennant, LL; Vahanian, NN; Yu, J; Zakharia, Y | 1 |
| Schmidt, C | 1 |
| Dréno, B; Khammari, A; Knol, AC; Le Naour, S; Pandolfino, MC | 1 |
1 trial(s) available for 1-methyltryptophan and Malignant Melanoma
| Article | Year |
|---|---|
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Tryptophan | 2021 |
5 other study(ies) available for 1-methyltryptophan and Malignant Melanoma
| Article | Year |
|---|---|
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; CTLA-4 Antigen; Cyclin-Dependent Kinase Inhibitor p16; Female; Humans; Immunotherapy; Ipilimumab; Male; Melanoma; Middle Aged; Mutation; Nivolumab; Programmed Cell Death 1 Receptor; Survival Analysis; Tryptophan; Tumor Suppressor Protein p53 | 2020 |
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Topics: Antineoplastic Agents; Cell Line, Tumor; Databases, Genetic; Drug Resistance, Neoplasm; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Melanoma; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Tryptophan; Vemurafenib | 2020 |
Highly uniform self-assembled microspheres from single macromolecule self-recognition for enhanced cancer immunotherapy.
Topics: Animals; Antibodies; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Synergism; Enzyme Inhibitors; Female; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Melanoma; Mice, Inbred C57BL; Microspheres; Polyethylene Glycols; Programmed Cell Death 1 Receptor; Tryptophan | 2020 |
The benefits of immunotherapy combinations.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Cancer Vaccines; Cell Cycle Checkpoints; Clinical Trials as Topic; Combined Modality Therapy; CTLA-4 Antigen; Drug Costs; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Ipilimumab; Lung Neoplasms; Male; Melanoma; Nivolumab; Oncolytic Virotherapy; Patient Selection; Precision Medicine; Programmed Cell Death 1 Receptor; Survival Analysis; T-Lymphocytes; Tryptophan; Tumor Escape | 2017 |
Effect of Indoleamine 2,3 Dioxygenase Inhibitor on the Cytotoxic Activity of Tumour-infiltrating Lymphocytes.
Topics: Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Lymphocytes, Tumor-Infiltrating; Melanoma; Skin Neoplasms; Tryptophan | 2019 |